Ibrutinib for the treatment of chronic lymphocytic leukemia

Bibliography

• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352(8):804-15
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Hatzi K, Albesiano E. B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens. Ann NY Acad Sci 2005;1062:1-12
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446-56
   PubMed Web of Science ®Google Scholar
• Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109(11):4679-85
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910-16
   PubMed Web of Science ®Google Scholar
• Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363(9403):105-11
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B-cells. Blood 1996;87(7):2615-20
   PubMed Web of Science ®Google Scholar
• Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011;2011:96-103
   PubMed Web of Science ®Google Scholar
• Deaglio S, Malavasi F. Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica 2009;94(6):752-6
   PubMed Web of Science ®Google Scholar
• Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 2008;264(6):549-62
   PubMed Web of Science ®Google Scholar
• Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B-cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96(8):2655-63
   PubMed Web of Science ®Google Scholar
• Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B-cells promoted by engagement of the antigen receptor. Blood 2001;98(10):3050-7
   PubMed Web of Science ®Google Scholar
• Longo PG, Laurenti L, Gobessi S, et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B-cells. Blood 2008;111(2):846-55
   PubMed Web of Science ®Google Scholar
• Muzio M, Scielzo C, Bertilaccio MT, et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009;144(4):507-16
   PubMed Web of Science ®Google Scholar
• Luqman M, Klabunde S, Lin K, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112(3):711-20
   PubMed Web of Science ®Google Scholar
• Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007;109(2):703-10
   PubMed Web of Science ®Google Scholar
• Buchner M, Baer C, Prinz G, et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010;115(22):4497-506
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Gibellini F, Njuguna N, et al. Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma 2011;52(9):1758-69
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117(2):563-74
   PubMed Web of Science ®Google Scholar
• Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B-cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102(8):1515-25
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104(9):2879-85
   PubMed Web of Science ®Google Scholar
• Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012;119(19):4467-75
   PubMed Web of Science ®Google Scholar
• Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200(4):519-25
   PubMed Web of Science ®Google Scholar
• Chu CC, Catera R, Hatzi K, et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008;112(13):5122-9
   PubMed Web of Science ®Google Scholar
• Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008;111(7):3838-48
   PubMed Web of Science ®Google Scholar
• Steininger C, Widhopf GF II, Ghia EM, et al. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood 2012;119(10):2293-301
   PubMed Web of Science ®Google Scholar
• Hoogeboom R, van Kessel KP, Hochstenbach F, et al. A mutated B-cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med 2013;210(1):59-70
   PubMed Web of Science ®Google Scholar
• Duhren-von Minden M, Ubelhart R, Schneider D, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012;489(7415):309-12
   PubMed Web of Science ®Google Scholar
• Binder M, Muller F, Jackst A, et al. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer 2011;117(9):1891-900
   PubMed Web of Science ®Google Scholar
• Chen L, Apgar J, Huynh L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005;105(5):2036-41
   PubMed Web of Science ®Google Scholar
• Guarini A, Chiaretti S, Tavolaro S, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008;112(3):782-92
   PubMed Web of Science ®Google Scholar
• Mockridge CI, Potter KN, Wheatley I, et al. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007;109(10):4424-31
   PubMed Web of Science ®Google Scholar
• Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008;112(1):188-95
   PubMed Web of Science ®Google Scholar
• Burger JA. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2012;7(1):26-33
   PubMed Web of Science ®Google Scholar
• Efremov D, Wiestner A, Laurenti L. Novel agents and emerging strategies for targeting the B-cell receptor pathway in CLL. Mediterr J Hematol Infect Dis 2012;4(1):e2012067
   Google Scholar
• Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011;118(16):4313-20
   PubMed Web of Science ®Google Scholar
• Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012;120(24):4684-91
   PubMed Web of Science ®Google Scholar
• Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012;120(6):1175-84
   PubMed Web of Science ®Google Scholar
• Davids MS, Brown JR. Targeting the B-cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma 2012;53(12):2362-70
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28(10):1756-65
   PubMed Web of Science ®Google Scholar
• Tam CS, Keating MJ. Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 2010;7(9):521-32
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114(16):3382-91
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007;48(10):1931-9
   PubMed Web of Science ®Google Scholar
• Tam CS, Wierda W, O'Brien S, et al. Life after fludarabine, cylcophosphamide, & rituximab (FCR) - the clinical outcome of patients with chronic lymphocytic leukemia who receive salvage treatment after frontline FCR [abstract]. Blood 2008;2090
   Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115(13):2578-85
   PubMed Web of Science ®Google Scholar
• Herman SE, Barr PM, McAuley EM, et al. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia 2013;27(8):1769-73
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31(1):88-94
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369(1):32-42
   PubMed Web of Science ®Google Scholar
• Coutre SE, Byrd JC, Furman RR, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2011;29(Suppl):[abstract 6631]
   Google Scholar
• Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30(5):488-96
   PubMed Web of Science ®Google Scholar
• Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11(12):1149-59
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19(2):202-8
   PubMed Web of Science ®Google Scholar
• Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2010;29(9):1175-81
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111(11):5291-7
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24(34):5343-9
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011;118(13):3489-98
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013;31(5):584-91
   PubMed Web of Science ®Google Scholar
• Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009;94(9):1266-73
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118(7):2427-37
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Ramsay AG, Zent CS, et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood 2013;121(20):4137-41
   PubMed Web of Science ®Google Scholar
• Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26(15):2519-25
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Hillmen P, Mahadevan D, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 2012;53(3):417-23
   PubMed Web of Science ®Google Scholar
• FDA. FDA halts clinical trial of drug Revlimid (lenalidomide) for chronic lymphocytic leukemia due to safety concerns. 2013. Available from: http://wwwfdagov/Drugs/DrugSafety/ucm361444htm
   Google Scholar
• Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012;31(2):119-32
   PubMed Web of Science ®Google Scholar
• Hendriks RW, Bredius RG, Pike-Overzet K, Staal FJ. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opin Ther Targets 2011;15(8):1003-21
   PubMed Web of Science ®Google Scholar
• Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007;2(1):58-61
   PubMed Web of Science ®Google Scholar
• Burger JA, Buggy JJ. Emerging drug profiles: bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 2013;[ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107(29):13075-80
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes. Blood 2013;[ Epub ahead of print]
   Web of Science ®Google Scholar
• Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117(23):6287-96
   PubMed Web of Science ®Google Scholar
• Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012;119(5):1182-9
   PubMed Web of Science ®Google Scholar
• de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012;119(11):2590-4
   PubMed Web of Science ®Google Scholar
• Kil LP, de Bruijn MJ, van Hulst JA, et al. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res 2013;3(1):71-83
   PubMedGoogle Scholar
• Herman SE, Sun X, McAuley EM, et al. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia 2013;27(8):1769-73
   PubMed Web of Science ®Google Scholar
• Herman SEM, Farooqui M, Bezabhie R, et al. In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients. ASH Annu Meet Abstr 2012;120(21):185
   Google Scholar
• Hoellenriegel J, O'Brien S, Keating MJ, et al. In vivo inhibition of BCR activation in high-risk CLL patients on therapy with Bruton's tyrosine kinase inhibitor ibrutinib: correlative studies from an ongoing phase 2 clinical trial. ASH Annu Meet Abstr 2012;120(21):186
   Google Scholar
• Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30(23):2820-2
   PubMed Web of Science ®Google Scholar
• Wiestner A. Single agent Ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukemia (CLL) patients with 17p deletion. Hematol Oncol 2013;31(S1):98
   Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Efficacy and safety of ibrutinib in combination with rituximab in high-risk cll patients. Hematol Oncol 2013;31(Suppl 1):193
   Google Scholar
• Jaglowski SM, Jones JA, Flynn JM, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol 2012;30(15 Suppl):6508
   Web of Science ®Google Scholar
• Brown J, Barrientos J, Flinn I, et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib combined with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL, interim results of a phase IB/II study. Abstract presented at the European Hematology Association Meeting; Amsterdam, The Netherlands; 2012
   Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369(6):507-16
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): interim results of a phase Ib/II study. J Clin Oncol 2012;30(Suppl):[abstract 6507]
   Google Scholar
• Chang BY, Furman RR, Zapatka M, et al. Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). J Clin Oncol 2013;31(Suppl 1):[abstract 7014]
   Google Scholar
• Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013;31(1):128-30
   PubMed Web of Science ®Google Scholar
• Experts in chronic myeloid leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121(22):4439-42
   PubMed Web of Science ®Google Scholar
• Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012;30(25):3127-35
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012;120(7):1412-21
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119(12):2709-20
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365(8):725-33
   PubMed Web of Science ®Google Scholar